Twist Bioscience
TWST
$84.95
+5.15%
Twist Bioscience is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's core competitive identity is as a technology disruptor, leveraging its proprietary semiconductor-based manufacturing process to synthesize DNA on silicon, enabling faster, more affordable, and scalable production compared to traditional methods. The current investor narrative is driven by the company's accelerating growth and its position as a key enabler in high-growth fields like next-generation sequencing tools and antibody discovery, with recent momentum likely fueled by strong quarterly revenue performance and its inclusion in high-profile innovation-focused portfolios, such as ARK Invest's ETFs, which has brought significant attention to the stock.…
TWST
Twist Bioscience
$84.95
Related headlines
Investment Opinion: Should I buy TWST Today?
Hold. The stock presents a high-risk, high-reward proposition where explosive growth potential is counterbalanced by severe valuation and profitability risks, making it suitable only for aggressive growth investors with a high risk tolerance.
The bullish thesis is supported by accelerating revenue growth (16.9% YoY), expanding gross margins (52.05% vs. 48.29% a year ago), and powerful technical momentum (126.5% annual return). Analyst sentiment is unanimously bullish, though coverage is limited. However, the bearish evidence is substantial: the company is deeply unprofitable (net margin -20.6%), burns significant cash (FCF -$86.7M), and trades at a demanding forward EV/Sales of 11.11x. The trailing PS ratio of 4.47x, while lower than its historical peak, still implies a premium expectation for future execution.
The rating would upgrade to Buy if the company demonstrates a clear path to positive operating cash flow in the next two quarters or if the stock price corrects 20-30% from current levels, improving the risk/reward profile. It would downgrade to Sell if quarterly revenue growth decelerates below 10% YoY or if the cash burn rate accelerates, threatening the balance sheet. Relative to its own history and the high-growth, pre-profit life science tools peer group, the stock is fairly valued to slightly overvalued, pricing in near-perfect execution.
Sign up to view all
TWST 12-Month Price Forecast
The 12-month outlook for TWST is bifurcated between its operational momentum and its precarious financial/valuation position. The base case (50% probability) sees the stock oscillating between $65 and $85 as growth continues but profitability remains elusive, preventing further multiple expansion. The bull case (25%) requires flawless execution and sector tailwinds to push the stock toward analyst high-end estimates, while the bear case (25%) is a sharp de-rating on any growth stumble. The AI assessment is Neutral with Medium confidence. The stance would upgrade to Bullish on concrete evidence of a path to positive free cash flow within 12 months. It would downgrade to Bearish on a quarterly revenue growth deceleration below 10% or a significant acceleration in cash burn.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Twist Bioscience's 12-month outlook, with a consensus price target around $110.44 and implied upside of +30.0% versus the current price.
Average Target
$110.44
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$68 - $110
Analyst target range
Analyst coverage for Twist Bioscience is limited, with only 3 analysts providing estimates, indicating this is a smaller-cap, high-growth story with less institutional scrutiny. The consensus sentiment is bullish, as evidenced by recent reiterated 'Buy', 'Overweight', and 'Outperform' ratings from firms like Barclays, Evercore ISI, and Guggenheim throughout early 2026, though no explicit price target data is provided in the dataset. The wide range of analyst estimates for future performance—with revenue estimates for the next period spanning from $781.8 million to $802.6 million and EPS estimates from $1.30 to $1.35—signals a degree of uncertainty around the precise growth trajectory, which is common for a company in a rapidly evolving market; the lack of a published average price target and the minimal number of analysts covering the stock suggests investors must rely more on their own fundamental and technical analysis rather than consensus views for price direction.
Bulls vs Bears: TWST Investment Factors
The bull case for TWST is compelling, built on accelerating revenue growth (16.9% YoY), expanding gross margins (52.05%), and a disruptive technology platform that is gaining traction. The bear case, however, is equally forceful, centered on persistent unprofitability, severe cash burn (-$86.7M FCF), and an extreme forward valuation (EV/Sales of 11.11x) that leaves no room for error. Currently, the bullish momentum is stronger, as evidenced by the stock's 126% annual return and unanimous analyst bullishness. However, the single most important tension in the investment debate is the race between accelerating revenue/margin expansion and the unsustainable cash burn rate. If growth decelerates before profitability is achieved, the high valuation and cash position could trigger a severe re-rating.
Bullish
- Accelerating Revenue Growth: Recent quarterly revenue grew 16.9% YoY to $103.7M, demonstrating accelerating top-line momentum. The company's two primary segments, NGS Tools and Antibody Discovery, are both contributing roughly $52M each, showing balanced growth drivers.
- Expanding Gross Margins: Gross margin improved to 52.05% in the last quarter, up from 48.29% a year ago, indicating the company's semiconductor-based manufacturing platform is becoming more efficient. This margin expansion is a critical step toward eventual profitability.
- Strong Technical Momentum: The stock has returned 126.5% over the past year and is trading at the 95th percentile of its 52-week range ($23.30 - $80.50), reflecting intense investor conviction. Recent momentum is extreme, with a 40% gain over the past month.
- Analyst Consensus Bullish: Limited analyst coverage (3 firms) is unanimously bullish, with recent reiterated 'Buy', 'Overweight', and 'Outperform' ratings. The average revenue estimate for the next period is $795M, implying continued growth expectations.
Bearish
- Persistent Unprofitability & Cash Burn: The company reported a net loss of -$30.5M last quarter with an operating margin of -36.18%. More critically, trailing twelve-month free cash flow is -$86.7M, indicating a significant cash burn that necessitates future capital raises.
- Extreme Valuation on Forward Sales: The forward EV/Sales multiple of 11.11x is exceptionally high, indicating the market is pricing in flawless execution of future growth and margin expansion. Any stumble in revenue growth could lead to severe multiple compression.
- Vulnerable Technical Position: Trading near its 52-week high of $80.50, the stock is technically overextended and vulnerable to a sharp pullback. Its beta of 2.21 means it is over 120% more volatile than the market, amplifying downside risk in a correction.
- Limited Analyst Coverage & Visibility: Only 3 analysts provide coverage, indicating lower institutional scrutiny and potentially less reliable consensus. The wide range in revenue estimates ($781.8M to $802.6M) also highlights uncertainty around the precise growth trajectory.
TWST Technical Analysis
The stock is in a powerful and sustained uptrend, having delivered a staggering 126.49% return over the past year, significantly outperforming the broader market. As of the latest close at $76.17, the price is trading at the 95th percentile of its 52-week range ($23.30 - $80.50), indicating it is testing multi-year highs, which reflects immense momentum but also suggests potential overextension and vulnerability to a pullback. Recent momentum has been exceptionally strong, with the stock gaining 40.04% over the past month and 76.00% over the past three months, far outpacing the S&P 500's returns of -0.08% and 12.00%, respectively, over the same periods; this acceleration from the longer-term trend signals intense bullish sentiment, potentially driven by recent earnings or sector-wide enthusiasm for synthetic biology. Key technical levels are clear, with immediate resistance at the 52-week high of $80.50 and support near the recent consolidation zone around the $50-$55 level; a decisive breakout above $80.50 would likely trigger a new leg higher, while a failure could lead to a sharp correction given the stock's extremely high beta of 2.21, which indicates it is over 120% more volatile than the market, amplifying both upside and downside moves.
Beta
2.21
2.21x market volatility
Max Drawdown
-38.2%
Largest decline past year
52-Week Range
$23-$87
Price range past year
Annual Return
+142.4%
Cumulative gain past year
| Period | TWST Return | S&P 500 |
|---|---|---|
| 1m | +72.8% | +1.5% |
| 3m | +91.1% | +13.4% |
| 6m | +166.1% | +10.9% |
| 1y | +142.4% | +24.5% |
| ytd | +162.3% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TWST Fundamental Analysis
Revenue growth is robust and accelerating, with the most recent quarterly revenue of $103.7 million representing a 16.9% year-over-year increase; this growth is being driven by its two primary segments, NGS Tools ($52.6M) and Antibody Discovery ($51.1M), which together show balanced contributions. The company remains unprofitable on a net income basis, reporting a loss of $30.5 million last quarter, though its gross margin of 52.05% is healthy and has expanded from 48.29% a year ago, indicating improving efficiency at the product level; however, operating losses persist, with an operating margin of -36.18% as high R&D and SG&A expenses continue to outpace gross profit. The balance sheet shows a strong liquidity position with a current ratio of 3.64, but cash flow generation is a significant concern, with trailing twelve-month free cash flow deeply negative at -$86.7 million and a negative free cash flow yield; the debt-to-equity ratio is a manageable 0.29, but the ongoing cash burn necessitates continued access to capital markets or a rapid path to operating profitability to sustain growth investments.
Quarterly Revenue
$103698000.0B
2025-12
Revenue YoY Growth
+0.16%
YoY Comparison
Gross Margin
+0.52%
Latest Quarter
Free Cash Flow
$-86724000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TWST Overvalued?
Given the company's negative net income, we lead with the Price-to-Sales (PS) ratio as the primary valuation metric. The trailing PS ratio stands at 4.47x, while the forward EV/Sales multiple is 11.11x; the significant premium of the forward multiple suggests the market is pricing in substantial future revenue growth and potential margin expansion. Compared to the broader Medical - Diagnostics & Research industry, Twist's PS ratio of 4.47x appears elevated, though a direct industry average is not provided in the data; typically, high-growth, pre-profitability life science tools companies trade at a premium, which may be justified if Twist can sustain its >15% revenue growth and demonstrate a credible path to profitability. Historically, the stock's own PS ratio has compressed dramatically from over 30x in late 2024 to the current 4.47x, indicating that while the share price has soared, revenue growth has accelerated even faster, making the valuation more reasonable relative to its own history and potentially leaving room for multiple expansion if execution continues.
PE
-21.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -41x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-31.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the unsustainable cash burn, with trailing twelve-month free cash flow at -$86.7 million. While the balance sheet shows a strong current ratio of 3.64 and manageable debt-to-equity of 0.29, the company's operating margin of -36.18% indicates it is far from self-sustaining. Revenue concentration is not a major issue, with balanced contributions from NGS Tools and Antibody Discovery, but earnings volatility is high, as shown by the swing from a $20.4M net income in Q3 2025 to a -$30.5M loss in Q1 2026. The company's valuation is entirely dependent on continued high revenue growth to justify its forward sales multiple.
Market & Competitive Risks: The stock's primary market risk is extreme valuation compression. Trading at a forward EV/Sales of 11.11x and near its 52-week high, any disappointment in growth or sector-wide de-rating of high-beta, unprofitable growth stocks could trigger a sharp sell-off. The stock's beta of 2.21 confirms it is highly sensitive to market movements. Competitive disruption is a constant threat in synthetic biology, and the company's technology advantage must be maintained through continued high R&D spending, which currently contributes to its losses. Recent news highlighting its inclusion in ARK Invest's portfolio has brought attention but also links its fate to the volatile thematic investing space.
Worst-Case Scenario: The worst-case scenario involves a combination of a growth scare (e.g., quarterly revenue deceleration below 10% YoY) coinciding with a broader market downturn that disproportionately hits high-beta, unprofitable stocks. This could trigger a rapid de-rating of the forward sales multiple from 11x towards 3-4x, coupled with a flight from momentum names. Given the stock's 52-week low of $23.30 and a maximum historical drawdown of -38.24%, a realistic downside from the current $76.17 could be a 50-60% correction to the $30-$38 range, representing a loss of -$38 to -$46 per share. This scenario would be exacerbated if the cash burn accelerates, forcing a dilutive equity raise at a depressed price.
FAQ
The key risks, in order of severity, are: 1) Financial Sustainability Risk: The company burns significant cash (-$86.7M TTM FCF) and is not yet profitable (operating margin -36.2%), requiring future capital raises. 2) Valuation & Momentum Risk: The stock trades near its 52-week high with a beta of 2.21, making it highly vulnerable to a sharp correction if growth expectations falter or market sentiment shifts. 3) Execution Risk: The high forward valuation (EV/Sales 11.11x) leaves no room for error; any slowdown in revenue growth from the current 16.9% pace could trigger a severe de-rating. 4) Competitive/Technology Risk: As a disruptor in synthetic biology, it must continuously innovate and defend its technological edge against well-funded competitors.
The 12-month forecast presents three scenarios with associated probabilities. The Base Case (50% probability) targets a range of $65-$85, assuming current growth (~16.9% YoY) and margin trends continue without a major catalyst or setback. The Bull Case (25% probability) targets $95-$115, requiring accelerated growth, margin expansion, and sustained market enthusiasm. The Bear Case (25% probability) targets $30-$50, triggered by a growth deceleration or earnings miss leading to multiple compression. The base case is most likely, but the wide range reflects the stock's high volatility and binary outcomes based on execution.
TWST appears fairly valued to slightly overvalued based on current fundamentals. Its trailing Price-to-Sales ratio of 4.47x is more reasonable than its historical levels above 30x, but its forward EV/Sales multiple of 11.11x is exceptionally high, indicating the market is pricing in several years of flawless growth and margin expansion. The valuation implies the market expects the company to successfully scale its disruptive platform and rapidly transition toward profitability. Any deviation from this optimistic growth trajectory would likely cause severe multiple compression, making the current price vulnerable.
TWST is a speculative buy, only suitable for investors with a high risk tolerance and a long-term horizon who believe in the disruptive potential of its DNA synthesis platform. The stock offers significant upside if the company can sustain its 16.9% revenue growth and achieve profitability, but it carries substantial downside risk due to its high valuation (forward EV/Sales of 11.11x), persistent cash burn (-$86.7M TTM), and extreme volatility (beta of 2.21). For most investors, a 'Hold' rating is prudent until there is clearer evidence of a path to sustainable cash flow generation.
TWST is unequivocally a long-term investment for investors who can withstand extreme volatility. Its high beta of 2.21 and lack of profitability make it unsuitable for short-term trading or income-seeking investors. The investment thesis is based on the multi-year adoption of its synthetic biology platform; realizing this potential will take time. A minimum holding period of 3-5 years is suggested to allow the company to execute its growth plan and potentially reach profitability, thereby de-risking the investment. Short-term traders would be exposed to excessive volatility driven by sentiment and momentum shifts.